Compare ConocoPhillips (COP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Inovio Pharmaceuticals Inc — how do they compare? ConocoPhillips trades at $112 (market cap $136.29B), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: ConocoPhillips is far larger — about 1421.9× Inovio Pharmaceuticals Inc's market cap, and ConocoPhillips pays a 3% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| COP | INO | |
|---|---|---|
Market Cap | $136.29B | $95.85M |
Sector | Energy | Health |
52-Week High | $133.80 | $2.87 |
52-Week Low | $85.66 | $1.05 |
Enterprise Value | $153.25B | $66.86M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $112.85, up 3.49% today, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported mixed Q1 2026 earnings, beating EPS estimates but showing declining revenue and net income margins since 2022. Recent news highlights oil price volatility and geopolitical risks influencing energy stocks.
COP offers value with a P/E of 19.13 and bullish analyst targets averaging $137.14, but faces headwinds from falling profitability and oil market instability. Investment appeal hinges on execution amid volatile commodity prices and competitive pressures.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
